Database : MEDLINE Search on : Rheumatic and Fever [Words] References found : 8971 [refine] Displaying: 1 .. 10   in format [Detailed]

page 1 of 898

go to page

1 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 23447639 [Au] Autor: Anderson NW; Buchan BW; Mayne D; Mortensen JE; Mackey TL; Ledeboer NA [Ad] Address: Medical College of Wisconsin, Milwaukee, Wisconsin, USA. [Ti] Title: Multicenter Clinical Evaluation of the illumigene Group A Streptococcus DNA Amplification Assay for Detection of Group A Streptococcus from Pharyngeal Swabs. [So] Source: J Clin Microbiol;51(5):1474-7, 2013 May. [Is] ISSN: 1098-660X [Cp] Country of publication: United States [La] Language: eng [Ab] Abstract: Acute pharyngitis is a nonspecific symptom that can result from a number of viral or bacterial infections. For most etiologies, symptoms are self-limited and resolve without lasting effects; however, pharyngitis resulting from infection with Streptococcus pyogenes (a group A Streptococcus [GAS]) can be associated with serious sequelae, including acute rheumatic fever and acute glomerulonephritis. Rapid accurate detection of GAS in pharyngeal specimens from individuals suffering from pharyngitis aids in the management and selection of antibiotic therapy for these patients. A total of 796 pharyngeal swabs were collected at three separate clinical centers. Each specimen was analyzed using the illumigene group A strep DNA amplification assay (Meridian Bioscience Inc., Cincinnati, OH). To confirm GAS identification, the results were compared to those from direct and extracted culture methods using Gram staining and a GAS-specific latex agglutination test. Discrepant results were resolved using an alternative nucleic acid amplification test. The prevalence of culture-detected GAS in this study was 12.8% (102/796 specimens). The illumigene assay detected GAS in 74/74 direct culture-positive specimens (100% sensitivity) and 100/102 extracted culture-positive specimens (98.0% sensitivity). GAS was detected by the illumigene assay in an additional 42 specimens that were direct culture negative (94.2% specificity) and 16 specimens that were extracted culture negative (97.7% specificity). Discrepant analysis using an alternative molecular assay detected GAS nucleic acid in 13/16 (81.3%) false-positive specimens and 1/2 false-negative specimens, resulting in a final sensitivity of 99.0% and a specificity of 99.6% for the detection of GAS in pharyngeal swabs using the illumigene assay. [Pt] Publication type: JOURNAL ARTICLE [Em] Entry month: 1304 [Js] Journal subset: IM [St] Status: In-Data-Review [do] DOI: 10.1128/JCM.00176-13

2 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 22753383 [Au] Autor: Ter Haar N; Lachmann H; Özen S; Woo P; Uziel Y; Modesto C; Koné-Paut I; Cantarini L; Insalaco A; Neven B; Hofer M; Rigante D; Al-Mayouf S; Touitou I; Gallizzi R; Papadopoulou-Alataki E; Martino S; Kuemmerle-Deschner J; Obici L; Iagaru N; Simon A; Nielsen S; Martini A; Ruperto N; Gattorno M; Frenkel J; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects [Ad] Address: Department of Paediatrics, University Medical Center Utrecht, Utrecht, The Netherlands. [Ti] Title: Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. [So] Source: Ann Rheum Dis;72(5):678-85, 2013 May. [Is] ISSN: 1468-2060 [Cp] Country of publication: England [La] Language: eng [Ab] Abstract: OBJECTIVE: To evaluate the response to treatment of autoinflammatory diseases from an international registry and an up-to-date literature review. METHODS: The response to treatment was studied in a web-based registry in which clinical information on anonymised patients with autoinflammatory diseases was collected retrospectively as part of the Eurofever initiative. Participating hospitals included paediatric rheumatology centres of the Paediatric Rheumatology International Trial Organisation network and adult centres with a specific interest in autoinflammatory diseases. The following diseases were included: familial Mediterranean fever (FMF), cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), pyogenic arthritis pustulosis acne (PAPA) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), NLRP12-related periodic fever and periodic fever aphthosis pharyngitis adenitis (PFAPA) syndrome. Cases were independently validated by experts for each disease. A literature search regarding treatment of the abovementioned diseases was also performed using Medline and Embase. RESULTS: 22 months from the beginning of the enrolment, complete information on 496 validated patients was available. Data from the registry in combination with evidence from the literature confirmed that colchicine is the treatment of choice for FMF and IL-1 blockade for DIRA and CAPS. Corticosteroids on demand probably represent a valid therapeutic strategy for PFAPA, but also for MKD and TRAPS. Patients with poorly controlled MKD, TRAPS, PAPA or FMF may benefit from IL-1 blockade; anti-TNF treatment may represent a possible valuable alternative. CONCLUSIONS: In the absence of high-grade evidence, these results could serve as a basis for therapeutic guidelines and to identify candidate drugs for future therapeutic trials. [Pt] Publication type: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Entry month: 1304 [Js] Journal subset: IM [St] Status: In-Process [do] DOI: 10.1136/annrheumdis-2011-201268

3 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 22646671 [Au] Autor: Rémond MG; Severin KL; Hodder Y; Martin J; Nelson C; Atkinson D; Maguire GP [Ad] Address: Cairns Clinical School, School of Medicine and Dentistry, Faculty of Medicine, Health and Molecular Sciences, James Cook University, Cairns, Queensland. marc.remond@my.jcu.edu.au [Ti] Title: Variability in disease burden and management of rheumatic fever and rheumatic heart disease in two regions of tropical Australia. [So] Source: Intern Med J;43(4):386-93, 2013 Apr. [Is] ISSN: 1445-5994 [Cp] Country of publication: Australia [La] Language: eng [Ab] Abstract: BACKGROUND: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) contribute to Aboriginal Australian and Torres Strait Islander health disadvantage. At the time of this study, specialist ARF/RHD care in the Kimberley region of Western Australia was delivered by a broad range of providers. In contrast, in Far North Queensland (FNQ), a single-provider model was used as part of a coordinated RHD control programme. AIMS: To review ARF/RHD management in the Kimberley and FNQ to ascertain whether differing models of service delivery are associated with different disease burden and patient care. METHODS: An audit of ARF/RHD management. Classification and clinical management data were abstracted from health records, specialist letters, echocardiograms and regional registers using a standardised data collection tool. RESULTS: Four hundred and seven patients were identified, with 99% being Aboriginal and/or Torres Strait Islanders. ARF without RHD was seen in 0.4% of Aboriginal and/or Torres Strait Islander residents and RHD in 1.1%. The prevalence of RHD was similar in both regions but with more severe disease in the Kimberley. More FNQ RHD patients had specialist review within recommended time frames (67% vs 45%, χ(2) , P < 0.001). Of patients recommended benzathine penicillin secondary prophylaxis, 17.7% received ≥80% of scheduled doses in the preceding 12 months. Prescription and delivery of secondary prophylaxis was greater in FNQ. CONCLUSIONS: FNQ's single-provider model of specialist care and centralised RHD control programme were associated with improved patient care and may partly account for the fewer cases of severe disease and reduced surgical procedures and other interventions observed in this region. [Pt] Publication type: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Entry month: 1304 [Js] Journal subset: IM [St] Status: In-Process [do] DOI: 10.1111/j.1445-5994.2012.02838.x

4 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 23239309 [Au] Autor: da Rocha Araújo FD; de Andrade Goulart EM; Meira ZM [Ad] Address: Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, fatima.derlene@hotmail.com. [Ti] Title: Use of Doppler echocardiography to support the decision to discontinue secondary prophylaxis for patients with rheumatic Fever and normal cardiac auscultation. [So] Source: Pediatr Cardiol;34(5):1073-80, 2013 Jun. [Is] ISSN: 1432-1971 [Cp] Country of publication: United States [La] Language: eng [Ab] Abstract: Secondary prophylaxis remains the safest way to prevent or minimize heart valve damage in patients with rheumatic fever. However, criteria to determine the duration of prophylaxis have not been well established. This study aimed to evaluate the clinical and Doppler echocardiographic profile of patients with rheumatic fever and a normal clinical examination at least 5 years after the first episode and to discuss the contribution of Doppler echocardiography in supporting the decision to discontinue secondary prophylaxis. An observational longitudinal study analyzing 183 patients with rheumatic fever and a normal clinical examination 5 years or more after the initial attack was conducted. The patients underwent Doppler echocardiography to study the severity of mitral or aortic valvular disease. Of the 183 patients, 77 (42 %) had clinical carditis. Subclinical chronic heart disease occurred for 79 % of the patients with previous clinical carditis and for 25 % of the patients without clinical carditis. Of the 35 patients with previous clinical carditis who were in the period of discontinued prophylaxis, residual valvular heart disease was observed in all, whereas of the 62 patients without clinical carditis, only 27 % showed residual valvular heart disease. Considering Doppler echocardiographic criteria, prophylaxis would be continued for 13 (34 %) of the patients with previous clinical carditis and for only 2 (3 %) of those without clinical carditis. Return of cardiac auscultation to normal is not always accompanied by return of Doppler echocardiographic findings to normal. Criteria regarding Doppler echocardiographic findings and valve morphology should be evaluated by the time secondary prophylaxis is discontinued. However, further studies are needed to demonstrate whether prolonged prophylaxis provides any benefit to patients with persistent echocardiographic findings. [Pt] Publication type: JOURNAL ARTICLE [Em] Entry month: 1305 [Js] Journal subset: IM [St] Status: In-Data-Review [do] DOI: 10.1007/s00246-012-0601-4

5 / 8971

MEDLINE

select to print Photocopy

[PMID]: 23661531 [Au] Autor: Fioretti M; Napodano S; Patti M; Rigante D [Ad] Address: Institute of Pediatrics, Catholic University of the Sacred Heart, Rome, Italy. drigante@gmail.com. [Ti] Title: Poststreptococcal glomerulonephritis and rheumatic fever: two faces of the same coin. [So] Source: Eur Rev Med Pharmacol Sci;17(8):1139-40, 2013 Apr. [Is] ISSN: 1128-3602 [Cp] Country of publication: Italy [La] Language: eng [Pt] Publication type: JOURNAL ARTICLE [Em] Entry month: 1305 [Js] Journal subset: IM [St] Status: In-Data-Review

6 / 8971

MEDLINE

select to print Photocopy PubMed Central Full text Full text

[PMID]: 23593359 [Au] Autor: Postol E; Alencar R; Higa FT; Freschi de Barros S; Demarchi LM; Kalil J; Guilherme L [Ad] Address: Heart Institute, School of Medicine, University of São Paulo, São Paulo, Brazil ; Institute for Immunology Investigation, National Institute of Science and Technology, University of São Paulo, São Paulo, Brazil. [Ti] Title: StreptInCor: A Candidate Vaccine Epitope against S. pyogenes Infections Induces Protection in Outbred Mice. [So] Source: PLoS One;8(4):e60969, 2013. [Is] ISSN: 1932-6203 [Cp] Country of publication: United States [La] Language: eng [Ab] Abstract: Infection with Streptococcus pyogenes (S. pyogenes) can result in several diseases, particularly in children. S. pyogenes M protein is the major virulence factor, and certain regions of its N-terminus can trigger autoimmune sequelae such as rheumatic fever in susceptible individuals with untreated group A streptococcal pharyngitis. In a previous study, we utilized a large panel of human peripheral blood cells to define the C-terminal protective epitope StreptInCor (medical identity), which does not induce autoimmune reactions. We recently confirmed the results in HLA-transgenic mice. In the present study, we extended the experimental assays to outbred animals (Swiss mice). Herein, we demonstrate high titers of StreptInCor-specific antibodies, as well as appropriate T-cell immune responses. No cross-reaction to cardiac myosin was detected. Additionally, immunized Swiss mice exhibited 87% survival one month after challenge with S. pyogenes. In conclusion, the data presented herein reinforce previous results in humans and animals and further emphasize that StreptInCor could be an effective and safe vaccine for the prevention of S. pyogenes infections. [Pt] Publication type: JOURNAL ARTICLE [Em] Entry month: 1304 [Js] Journal subset: IM [St] Status: In-Data-Review [do] DOI: 10.1371/journal.pone.0060969

7 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 22872049 [Au] Autor: Ding Y; Ni Q; Liu J; Yu B [Ad] Address: Department of Cardiology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 510700, China. [Ti] Title: Immunogenicity of a divalent group A streptococcal vaccine. [So] Source: Rheumatol Int;33(4):1013-20, 2013 Apr. [Is] ISSN: 1437-160X [Cp] Country of publication: Germany [La] Language: eng [Ab] Abstract: We designed and recombined the polypeptide based on the M protein of group A streptococci (GAS)--the causative pathogen of rheumatic fever and rheumatic heart disease, which would be a divalent vaccine to prevent and defend the diseases in relation to the different GAS strains. A divalent vaccine comprising three different peptide epitopes of the antiphagocytic M protein of GAS--an aminoterminal specific sequences, respectively, from the M1 and M12 proteins and J14 peptide (ASREAKKQVEKALE) within the highly conserved C-terminal repeat region of the M1 and M12 proteins--was subcutaneously delivered to mice with the adjuvant. Furthermore, the antisera titers of mice inoculated with the divalent vaccine were assayed by ELISA, and then opsonization and percentage killing against two different GAS serotypes were completed. Our data demonstrated that antisera raised against the divalent vaccine containing amino acids and M-protein-conserved C repeat region are able to kill several GAS strains isolated from the Guangzhou population. Therefore, the divalent vaccine can be used to prevent those diseases caused by GAS in an endemic area. We successfully construct the M-protein-based divalent vaccine that can bring out a high-level antisera titer of mice vaccinated with it. So, the vaccine has the potential to be used to prevent diseases caused by GAS in our country. [Pt] Publication type: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Entry month: 1304 [Js] Journal subset: IM [St] Status: In-Process [do] DOI: 10.1007/s00296-012-2455-8

8 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 22307925 [Au] Autor: Santos IS; Benseñor IM; Machado JB; Fedeli LM; Lotufo PA [Ad] Address: University of São Paulo Medical School, Internal Medicine Department, São Paulo, Brazil. itamarss@usp.br [Ti] Title: Intervention to reduce C-reactive protein determination requests for acute infections at an emergency department. [So] Source: Emerg Med J;29(12):965-8, 2012 Dec. [Is] ISSN: 1472-0213 [Cp] Country of publication: England [La] Language: eng [Ab] Abstract: INTRODUCTION: C-reactive protein (CRP) levels rise during inflammatory processes and have been ordered for rheumatic disease follow-up since the 1950s. The number of tests ordered in the emergency setting has increased, but without evident improvement in medical care quality. OBJECTIVE: To determine the pattern of CRP determinations in the emergency department (ED) of a university hospital in Sao Paulo, Brazil, and to evaluate the effect of an intervention with staff and students about the best use of the test in the ED. METHODS: Data regarding CRP testing requests, related diagnoses and the number of monthly consultations in the hospital ED were analysed before and after the intervention. Because of an increase in CRP measurement requests from 2007 to 2009, the author started discussing the role of CRP determinations in the medical decision-making process in early 2010. Staff and faculty members openly discussed the pattern of requests in the hospital and related current medical literature. During 2010, the medical staff worked as multipliers to change the behaviour of new students and residents. The results of the first 4 months after the intervention were presented at another general meeting in July 2010. RESULTS: From 2007 to 2009, there were 11,786 CRP measurement requests with a clear exponential trend. After the intervention, during the calendar year 2010, there was a 48% reduction in adjusted annual CRP requests. Pneumonia, fever and urinary tract infections were the most common reasons for CRP requests. DISCUSSION: Inexpensive, well-directed, interactive educational interventions may affect professional behaviour and curb rates of laboratory tests. [Mh] MeSH terms primary: C-Reactive Protein/analysis Clinical Chemistry Tests/utilization Emergency Service, Hospital/statistics & numerical data Infection/diagnosis [Mh] MeSH terms secundary: Acute Disease Biological Markers/analysis Brazil Hospitals, University Humans Regression Analysis [Pt] Publication type: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Name of substance: 0 (Biological Markers); 9007-41-4 (C-Reactive Protein) [Em] Entry month: 1305 [Js] Journal subset: IM [Da] Date of entry for processing: 121126 [St] Status: MEDLINE [do] DOI: 10.1136/emermed-2011-200787

9 / 8971

MEDLINE

select to print Photocopy PubMed Central Full text Full text

[PMID]: 23155374 [Au] Autor: Lerner AM; Ariza ME; Williams M; Jason L; Beqaj S; Fitzgerald JT; Lemeshow S; Glaser R [Ad] Address: Department of Medicine, Oakland University William Beaumont School of Medicine, Rochester, Michigan, United States of America. amartinlerner@yahoo.com [Ti] Title: Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset. [So] Source: PLoS One;7(11):e47891, 2012. [Is] ISSN: 1932-6203 [Cp] Country of publication: United States [La] Language: eng [Ab] Abstract: BACKGROUND: A defined diagnostic panel differentiated patients who had been diagnosed with chronic fatigue syndrome (CFS), based upon Fukuda/Carruthers criteria. This diagnostic panel identified an Epstein-Barr virus (EBV) subset of patients (6), excluding for the first time other similar "clinical" conditions such as cytomegalovirus (CMV), human herpesvirus 6 (HHV6), babesiosis, ehrlichiosis, borreliosis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and adult rheumatic fever, which may be mistakenly called CFS. CFS patients were treated with valacyclovir (14.3 mg/kg q6h) for ≥ 12 months. Each patient improved, based upon the Functional Activity Appraisal: Energy Index Score Healthcare Worker Assessment (EIPS), which is a validated (FSS-9), item scale with high degree of internal consistency measured by Cronbach's alpha. METHODS: Antibody to EBV viral capsid antigen (VCA) IgM, EBV Diffuse Early Antigen EA(D), and neutralizing antibodies against EBV-encoded DNA polymerase and EBV-encoded dUTPase were assayed serially approximately every three months for 13-16 months from sera obtained from patients with CFS (6) and from sera obtained from twenty patients who had no history of CFS. RESULTS: Antibodies to EBV EA(D) and neutralizing antibodies against the encoded-proteins EBV DNA polymerase and deoxyuridine triphosphate nucleotidohydrolase (dUTPase) were present in the EBV subset CFS patients. Of the sera samples obtained from patients with CFS 93.9% were positive for EA(D), while 31.6% of the control patients were positive for EBV EA(D). Serum samples were positive for neutralizing antibodies against the EBV-encoded dUTPase (23/52; 44.2%) and DNA polymerase (41/52; 78.8%) in EBV subset CFS patients, but negative in sera of controls. CONCLUSIONS: There is prolonged elevated antibody level against the encoded proteins EBV dUTPase and EBV DNA polymerase in a subset of CFS patients, suggesting that this antibody panel could be used to identify these patients, if these preliminary findings are corroborated by studies with a larger number of EBV subset CFS patients. [Mh] MeSH terms primary: Antibodies, Neutralizing/immunology Fatigue Syndrome, Chronic/immunology Herpesvirus 4, Human/genetics Herpesvirus 4, Human/immunology [Mh] MeSH terms secundary: Adult Antigens, Viral DNA-Directed DNA Polymerase/immunology Fatigue Syndrome, Chronic/virology Female Humans Male Middle Aged Pyrophosphatases/immunology [Pt] Publication type: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL [Nm] Name of substance: 0 (Antibodies, Neutralizing); 0 (Antigens, Viral); 0 (Epstein-Barr virus early antigen); EC 2.7.7.7 (DNA-Directed DNA Polymerase); EC 3.6.1.- (Pyrophosphatases); EC 3.6.1.23 (dUTP pyrophosphatase) [Em] Entry month: 1305 [Js] Journal subset: IM [Da] Date of entry for processing: 121116 [St] Status: MEDLINE [do] DOI: 10.1371/journal.pone.0047891

10 / 8971

MEDLINE

select to print Photocopy Full text

[PMID]: 23052403 [Au] Autor: Bolten WW; Reiter S; und die Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie [Ad] Address: Abt. Rheumatologie, Klaus Miehlke Klinik, Leibnizstr. 23, 65191, Wiesbaden, Deutschland. wbolten@em.uni-frankfurt.de [Ti] Title: Empfehlungen zur symptomatischen Therapie mit Opioidanalgetika bei rheumatischen Schmerzen. [Recommendations for symptomatic therapy of rheumatic pain with opioid analgetics]. [So] Source: Z Rheumatol;71(9):816-22, 2012 Nov. [Is] ISSN: 1435-1250 [Cp] Country of publication: Germany [La] Language: ger [Ab] Abstract: The treatment of musculoskeletal pain is often difficult. For this reason opioids are increasingly being used for chronic musculoskeletal complaints despite poor or lacking evidence for their pain relieving and function improving effects. However, side effects are common and can be severe. Opioid-induced hyperalgesia can lead to higher doses and stronger pain and increase the risk of side effects. Long-term treatment of rheumatic pain with opioids should be carried out with caution. [Mh] MeSH terms primary: Analgesics, Opioid/therapeutic use Arthralgia/etiology Arthralgia/prevention & control Palliative Care/standards Rheumatic Fever/complications Rheumatic Fever/drug therapy Rheumatology/standards [Mh] MeSH terms secundary: Analgesics, Opioid/adverse effects Germany Humans [Pt] Publication type: ENGLISH ABSTRACT; JOURNAL ARTICLE [Nm] Name of substance: 0 (Analgesics, Opioid) [Em] Entry month: 1305 [Js] Journal subset: IM [Da] Date of entry for processing: 121109 [St] Status: MEDLINE [do] DOI: 10.1007/s00393-012-1026-4

---

page 1 of 898

go to page

Refine the search

Database : MEDLINE

Advanced form

		Search	in field
1			WordsSubject descriptorMajor Subject descriptorLimitsAuthorTitle wordsAbstract wordsLanguageCountry of publicationName of substancePersonal name as subjectJournalJournal DescriptorISSNPublication typeUnique identifierEntry monthYear of PublicationFulltextClass update dateDeCS CategoryDeCS Category explodedICD-10 CategorySubSetsAffiliation CountryAffiliation
2	and or and not		WordsSubject descriptorMajor Subject descriptorLimitsAuthorTitle wordsAbstract wordsLanguageCountry of publicationName of substancePersonal name as subjectJournalJournal DescriptorISSNPublication typeUnique identifierEntry monthYear of PublicationFulltextClass update dateDeCS CategoryDeCS Category explodedICD-10 CategorySubSetsAffiliation CountryAffiliation
3	and or and not		WordsSubject descriptorMajor Subject descriptorLimitsAuthorTitle wordsAbstract wordsLanguageCountry of publicationName of substancePersonal name as subjectJournalJournal DescriptorISSNPublication typeUnique identifierEntry monthYear of PublicationFulltextClass update dateDeCS CategoryDeCS Category explodedICD-10 CategorySubSetsAffiliation CountryAffiliation

Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information